|
 |
tenofovir disoproxil fumarateThis page contains recent news articles, when available, and an overview of tenofovir disoproxil fumarate but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.FDA approval for the company's fixed-dose combination of Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate tablets for the treatment of HIV. ... TransWorldNews (press release) Generic Name: efavirenz, emtricitabine, tenofovir - Nov 11, 2009 Atripla (generic name: efavirenz / emtricitabine / tenofovir disoproxil fumarate) is a combination medicine used alone or with other medicines to treat ... Pattaya Daily News Gilead finds Viread sustains suppression of hepatitis B - Nov 2, 2009 Gilead Sciences announced results of phase 3 studies conducted over three years of the drug Viread (tenofovir disoproxil fumarate), which the company will ... Drug Store News (blog) HIV/AIDS Update - Tentative Approval of Lamivudine and Tenofovir DF Fixed Dose ... - Nov 6, 2009 ...the Food and Drug Administration (FDA), granted tentative approval for lamivudine and tenofovir disoproxil fumarate fixed dose combination tablets, ... PharmaLive (press release) (subscription) FDA Approves Labeling Update for REYATAZ® (atazanavir sulfate) Capsules to ... - Nov 5, 2009 Each was given in combination with a once-daily, fixed-dose combination of tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg. ... WELT ONLINE GileadAnnouncesLong-TermDatafromTwo PivotalPhaseIIIStudiesEvaluatingViread ... - Oct 31, 2009 Important Information About Viread for Chronic Hepatitis B and HIV Viread (tenofovir disoproxil fumarate) is indicated for the treatment of chronic ... Reuters FDA OKs Labeling Update for Reyataz Capsules - Nov 9, 2009 Each was given in combination with a once-daily, fixed-dose combination of tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg. ... Trading Markets (press release) … FDA Approval Under PEPFAR for Tenofovir Disoproxil Fumarate Tablets... - Dec 4, 2007 Matrix's Tenofovir Disoproxil Fumarate is the first and only generic tentative approval of Gilead Sciences Inc.'s Viread Tablets, 300 mg. ... Free with registration - PR Newswire - AccessMyLibrary.com Tenofovir Disoproxil Fumarate Oral : User Ratings covering uses, … - Jun 17, 2008 ...in tandem with ritonavir, emtricitabine, fosamprenavir, cells up, load undetectable, some opioid withdrawal temporarily upon taking, but otherwise digests ... WebMD US Food and Drug Administration (FDA) Approves ATRIPLA(TM) ( … - Jul 12, 2006 Truvada itself is a fixed-dose product that contains two of Gilead's anti-HIV medications, Viread(R) (tenofovir disoproxil fumarate) and Emtriva(R) ... Free with registration - PR Newswire - AccessMyLibrary.com Tenofovir Disoproxil Fumarate Approved in Europe for Treatment of … - Apr 25, 2008 NEW YORK -- April 25, 2008 -- The European Commission has granted marketing authorisation for tenofovir disoproxil fumarate (Viread) for the treatment of ... DG News … the co-administration of tenofovir disoproxil fumarate (TDF,... - Mar 6, 2005 The co-administration of tenofovir disoproxil fumarate and didanosine is not recommended within any antiretroviral combination therapy, and particularly in ... i-newswire.com … the co-administration of tenofovir disoproxil fumarate (TDF,... - Mar 4, 2005 The co-administration of tenofovir disoproxil fumarate and didanosine is not recommended within any antiretroviral combination therapy, and particularly in ... Medical News Today - Medical News Today (press release) … AND TENOFOVIR DISOPROXIL FUMARATE (Oral route) - em-trye-SYE- … - May 1, 2007 Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone or in combination ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com … FDA Approval Under PEPFAR for Tenofovir Disoproxil Fumarate Tablets... - Dec 4, 2007 Mylan Announces Tentative FDA Approval Under PEPFAR for Tenofovir Disoproxil Fumarate Tablets. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Tenofovir disoproxil fumarate and an optimized background regimen of ... - Sep 1, 2006 Rachel I. Gafni, MDb, Rohan Hazra, MD, James C. Reynolds, MD, Frank Maldarelli, MD, PhD, Antonella N. Tullio, MD, Ellen DeCarlo, BSN, Carol J. Worrell, MD, ... $4.95 - Pediatrics - ECNext Bloomberg Printer-Friendly Page - Dec 11, 2007 Emtricitabine and tenofovir disoproxil fumarate are commercialized by Gilead under the tradenames Emtriva(R) and Viread(R), respectively, and are commonly ... Bloomberg Netherlands Corporate News - Amerikaanse Food and Drug … - Dec 7, 2006 Truvada itself is a fixed-dose product that contains two of Gilead's anti-HIV medications, Viread(R) (tenofovir disoproxil fumarate) and Emtriva(R) ... Netherlands Corporate News - Netherlands Corporate News (persbericht) Bristol-Myers Squibb and Gilead Sciences Establish Agreement to … - Sep 28, 2006 Truvada itself is a fixed-dose product that contains two of Gilead's anti-HIV medications, Viread(R) (tenofovir disoproxil fumarate) and Emtriva(R) ... Genetic Engineering News - Genetic Engineering News (press release) FDA Grants Approval To First Generic For Antiretroviral Viread - Dec 19, 2007 Tenofovir disoproxil fumarate is the latest addition of an ... FDA reviewed this application for generic tenofovir disoproxil fumarate tablets in less than ... emaxhealth.com Gilead Sciences and Merck Establish Agreement for Distribution of … - Aug 11, 2006 Emtricitabine and tenofovir disoproxil fumarate are commercialized by Gilead Sciences under the tradenames Emtriva(R) and Viread(R), respectively. ... Free with registration - Business Wire - AccessMyLibrary.com Brazil rejects tenofovir patent - Sep 5, 2008 In Brazil Gilead sought a patent for tenofovir disoproxil fumarate rather than tenofovir disoproxil, the intermediate ingredient. ... Aidsmap Bristol-Myers Squibb, Gilead Sciences And Merck & Co. Submit Marketing... - Oct 10, 2006 Emtricitabine and tenofovir disoproxil fumarate are commercialized by Gilead Sciences under the tradenames Emtriva(R) and Viread(R), respectively. ... Medical News Today - Medical News Today (press release) Netherlands Corporate News - Bristol-Myers Squibb en Gilead Sciences ... - Nov 12, 2007 Emtricitabine and tenofovir disoproxil fumarate are commercialized by Gilead under the tradenames Emtriva(R) and Viread(R), respectively, and are commonly ... Netherlands Corporate News - Netherlands Corporate News (persbericht) Business Update; Global Access Program for HIV therapies to include … - Apr 16, 2005 The Gilead Access Program makes Gilead's Truvada (emtricitabine and tenofovir disoproxil fumarate) and Viread (tenofovir disoproxil fumarate) available to ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Gilead, Merck to collaborate on HIV drug distribution in 12 countries - Aug 1, 2008 Emtricitabine and tenofovir disoproxil fumarate are commercialized by Gilead Sciences under the tradenames Emtriva and Viread, respectively, and together as ... Bizjournals.com Bristol-Myers Squibb And Gilead Sciences Announce Health Canada … - Oct 17, 2007 This product combines Sustiva or efavirenz, manufactured by Bristol-Myers, and Truvada or emtricitabine/tenofovir disoproxil fumarate, manufactured by ... $4.95 - M2 Presswire - ECNext Netherlands Corporate News - Gilead komt met update over ontwikkeling... - Sep 8, 2005 Guidelines issued by the US Department of Health and Human Services (DHHS) list the combination of emtricitabine, tenofovir disoproxil fumarate and ... Netherlands Corporate News - Netherlands Corporate News (persbericht) Bristol-Myers Squibb, Gilead Sciences and Merck & Co. Submit … - Oct 9, 2006 Emtricitabine and tenofovir disoproxil fumarate are commercialized by Gilead Sciences under the tradenames Emtriva([R]) and Viread([R]), respectively. ... Free with registration - Business Wire - AccessMyLibrary.com Netherlands Corporate News - Gilead Sciences meldt financiÄ—le … - Jan 23, 2008 Viread Sales of Viread(R) (tenofovir disoproxil fumarate) were $148.5 million in the fourth quarter of 2007, a seven percent decrease from $159.5 million in ... Netherlands Corporate News - Netherlands Corporate News (persbericht) Truvada combo a no go? - Aug 22, 2005 Analysts are bullish that Gilead can stand on the success of Truvada, itself a fixed dose combination (FDC) tablet of Viread (tenofovir disoproxil fumarate) ... ICIS Gilead Sciences Announces First Quarter 2008 Financial Results - Apr 16, 2008 Sales of Viread(R) (tenofovir disoproxil fumarate) were $152.7 million in the first quarter of 2008, a five percent decrease from $160.7 million in the ... Genetic Engineering News - Genetic Engineering News (press release) 96-Week Data From Gilead's Study 934 Comparing Viread(R) and … - Dec 15, 2006 The study article, "Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in ... RedOrbit GB AIDS Drugs Plant “Pivotalâ€? - Sep 6, 2005 Gilead announced a significant price reduction for Viread [tenofovir disoproxil fumarate] and Truvada [emtricitabine and tenofovir disoproxil fumarate] ... Bahama Journal - The Bahama Journal Netherlands Corporate News - Gilead Sciences meldt derde … - Oct 19, 2007 Viread Sales of Viread(R) (tenofovir disoproxil fumarate) were $149.1 million in the third quarter of 2007, a 13 percent decrease from $170.6 million in the ... Netherlands Corporate News - Netherlands Corporate News (persbericht) Tenofovir Approved for Treatment of Chronic Hepatitis B in Adults - Aug 12, 2008 Tenofovir disoproxil fumarate is also indicated for the treatment of chronic hepatitis B in adults. The drug is administered as a once-daily tablet and ... DG News Bristol-Myers Squibb and Gilead Sciences Submit New Drug Application ... - Apr 27, 2006 The proposed once-daily single tablet regimen contains 600 mg of efavirenz, 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate. ... RedOrbit Gilead Gets Letairis Approval, Potential Best In Class For PAH - Jun 19, 2007 ...drugs Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), Truvada (emtricitabine and tenofovir disoproxil fumarate), ... BioWorld Online - BioWorld Online Gilead Provides Update on Development of Fixed-Dose Regimen of … - Apr 26, 2005 Guidelines issued by the US Department of Health and Human Services (DHHS) list the combination of emtricitabine, tenofovir disoproxil fumarate and ... $4.95 - Business Wire - ECNext JB Chemicals ties up with US firm for anti-HIV drug - Sep 22, 2006 Tenofovir disoproxil fumarate is sold by Gilead under the brand name Viread (R), JB Chemicals said in a communiqué on the Bombay Stock Exchange today. ... Siliconindia.com Matrix Lab gets tentative nod for HIV drugs - Sep 16, 2008 Tenofovir disoproxil fumarate is used in combination with other antiretroviral agents in the treatment of HIV infections in adults. ... Myiris.com Netherlands Corporate News - Bristol-Myers Squibb, Gilead Sciences en... - Sep 10, 2006 Emtricitabine and tenofovir disoproxil fumarate are commercialized by Gilead Sciences under the tradenames Emtriva(R) and Viread(R), respectively. ... Netherlands Corporate News - Netherlands Corporate News (persbericht) Gilead Sciences Announces Fourth Quarter and Full Year 2006 Financial... - Jan 31, 2007 ...including the strong uptake of Atripla(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) following its launch in July ... Free with registration - Business Wire - AccessMyLibrary.com Gilead Sciences Announces Second Quarter 2008 Financial Results - Jul 17, 2008 Viread(R) (tenofovir disoproxil fumarate) sales were $150.7 million for the second quarter of 2008, a three percent decrease from $154.9 million in the ... Genetic Engineering News - Genetic Engineering News (press release) Netherlands Corporate News - Voorbereidende 24-weekse data betreft … - Nov 17, 2005 The parent compound of one of the component drugs in Truvada, tenofovir disoproxil fumarate, was discovered through a collaborative research effort between ... Netherlands Corporate News - Netherlands Corporate News (persbericht) Netherlands Corporate News - Gilead Sciences en Merck distribueren … - Nov 8, 2006 Emtricitabine and tenofovir disoproxil fumarate are commercialized by Gilead Sciences under the tradenames Emtriva(R) and Viread(R), respectively. ... Netherlands Corporate News - Netherlands Corporate News (persbericht) Gilead Sciences Announces Second Quarter 2007 Financial Results - Jul 19, 2007 Sales of Viread(R) (tenofovir disoproxil fumarate) were $154.9 million in the second quarter of 2007, a seven percent decrease from $167.4 million in the ... Genetic Engineering News - Genetic Engineering News (press release) Netherlands Corporate News - Europees CHMP geeft positief advies … - Mar 20, 2008 About Viread (tenofovir disoproxil fumarate) for HIV In the United States, Viread is indicated in combination with other antiretroviral agents for the ... Netherlands Corporate News - Netherlands Corporate News (persbericht) European Commission approves Truvada, a once-a-day tablet containing … - Feb 23, 2005 Gilead Sciences announced that the European Commission has granted a Marketing Authorisation for Truvada (emtricitabine and tenofovir disoproxil fumarate) ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com European CHMP Issues Positive Opinion For ATRIPLA(R) (Efavirenz … - Oct 22, 2007 Emtricitabine and tenofovir disoproxil fumarate are commercialized by Gilead under the tradenames Emtriva(R) and Viread(R), respectively, and are commonly ... Medical News Today - Medical News Today (press release) Gilead Provides Update on Development of Fixed-Dose Regimen of … - Aug 9, 2005 Guidelines issued by the US Department of Health and Human Services (DHHS) list the combination of emtricitabine, tenofovir disoproxil fumarate and ... $4.95 - Business Wire - ECNext FDA Approves Viread for Chronic Hepatitis B in Adults - Aug 12, 2008 Viread (tenofovir disoproxil fumarate) is indicated for the treatment of chronic hepatitis B in adults. * This indication is based on data from one year of ... emaxhealth.com Bristol-Myers Squibb And Gilead Announce Data Supporting … - Jan 9, 2006 Guidelines issued by the US Department of Health and Human Services (DHHS) list the combination of emtricitabine, tenofovir disoproxil fumarate and ... webwire.com Merck & Co., Inc. (1) To Distribute ATRIPLA(TM) in Developing … - Feb 16, 2007 Emtricitabine and tenofovir disoproxil fumarate are commercialized by Gilead Sciences under the tradenames Emtriva([R]) and Viread([R]), respectively. ... Free with registration - Business Wire - AccessMyLibrary.com Gilead Sciences Announces Third Quarter 2008 Financial Results - Oct 16, 2008 Viread(R) (tenofovir disoproxil fumarate) sales increased five percent to $156.0 million for the third quarter of 2008 from $149.1 million in the third ... Genetic Engineering News - Genetic Engineering News (press release) Netherlands Corporate News - Gilead meldt gegevens overstap van … - Oct 29, 2007 Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued Viread(R) (tenofovir disoproxil fumarate) or Emtriva(R) ... Netherlands Corporate News - Netherlands Corporate News (persbericht) Japan Tobacco licenses novel HIV integrase inhibitor to Gilead... - Mar 28, 2005 ...when Gilead granted Japan Tobacco the commercialization rights for the HIV agents Truvada (emtricitabine and tenofovir disoproxil fumarate),Viread ... $4.95 - Pharma Marketletter - ECNext Gilead signs agreement with Indian companies to produce Viread - Aug 17, 2006 Gilead sells tenofovir disoproxil fumarate under the brand name Viread. "We are pleased to have finalised agreements with Emcure, Hetero and Strides Arcolab ... Free with registration - PTI - The Press Trust of India Ltd - AccessMyLibrary.com European CHMP Issues Positive Opinion For ATRIPLA(R) (efavirenz 600 … - Oct 19, 2007 Emtricitabine and tenofovir disoproxil fumarate are commercialized by Gilead under the tradenames Emtriva(R) and Viread(R), respectively, and are commonly ... Medical News Today - Medical News Today (press release) eLab - Pharmacology ARV choices explored - Jul 9, 2008 In its tablet form, tenofovir disoproxil fumarate, known by the brand name Viread, is a mainstay of one of the most widely used regimens for treating HIV. ... Scientist Live Gilead and Japan Tobacco pen HIV licensing deal - Mar 23, 2005 ...rights for Truvada (emtricitabine and tenofovir disoproxil fumarate), Viread (tenofovir disoproxil fumarate) and Emtriva (emtricitabine) in Japan. ... Pay-Per-View - Datamonitor News and Comment - Factiva, from Dow Jones 144-Week Data From Gilead's Study 934 Comparing Truvada(R) to … - Jul 23, 2007 Truvada is a fixed-dose combination tablet containing 200 mg of emtricitabine (Emtriva) and 300 mg of tenofovir disoproxil fumarate (Viread). ... RedOrbit Article: New drug combination to be tested in people to block AIDS... - May 11, 2006 Business Wire; August 29, 2005 ; 700+ words ... ... tenofovir disoproxil fumarate) and Truvada(R) (emtricitabine and tenofovir disoproxil ... pharmaceutical ... Pay-Per-View - San Jose Mercury News - HighBeam Research Netherlands Corporate News - Gilead dient marktapplicaties in bij … - Dec 10, 2007 About Viread (tenofovir disoproxil fumarate) for HIV In the United States, Viread is indicated in combination with other antiretroviral agents for the ... Netherlands Corporate News - Netherlands Corporate News (persbericht) Gilead Sciences Announces First Quarter 2007 Financial Results - Apr 18, 2007 Sales of Viread(R) (tenofovir disoproxil fumarate) were $160.7 million in the first quarter of 2007, a 16 percent decrease from $191.8 million in the first ... Genetic Engineering News - Genetic Engineering News (press release) Gilead beats consensus; HIV drugs drive growth.(Thursday, October 20) - Oct 24, 2005 Gilead's combined HIV drug, Truvada (emtricitabine and tenofovir disoproxil fumarate), recorded sales of $162.4 million, a 32 percent increase over the ... Pay-Per-View - BioWorld Week - Factiva, from Dow Jones Article: Foster City firm's AIDS drug ready for human trials. - San... - May 12, 2006 Business Wire; August 29, 2005 ; 700+ words ... ... tenofovir disoproxil fumarate) and Truvada(R) (emtricitabine and tenofovir disoproxil ... pharmaceutical ... Pay-Per-View - San Jose Mercury News - HighBeam Research Gilead shifts Irish ops - Apr 12, 2007 Truvada (emtricitabine and tenofovir disoproxil fumarate) and Viread (emtricitabine and tenofovir disoproxil fumarate) - all for the treatment of HIV ... In-PharmaTechnologist.com HIV Prevention Researchers To Compare Common ARV As A Pill And … - Jul 11, 2008 In its tablet form, tenofovir disoproxil fumarate, known by the brand name Viread, is a mainstay of one of the most widely used regimens for treating HIV. ... Medical News Today - Medical News Today (press release) Merger and Acquisition Scenario - Mar 11, 2006 Gilead markets Viread (tenofovir disoproxil fumarate), Emtriva (emtricitabine) and Truvada (emtricitabine and tenofovir disoproxil fumarate) for the ... $250.00 - Revere Reports - Revere Press Release: Bristol-Myers Squibb and Gilead Sciences Establish … - Sep 28, 2006 Truvada itself is a fixed-dose product that contains two of Gilead's anti-HIV medications, Viread(R) (tenofovir disoproxil fumarate) and Emtriva(R) ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Bristol-Myers Squibb, Gilead Sciences and Merck & Co. ... - Oct 9, 2006 Emtricitabine and tenofovir disoproxil fumarate are commercialized by Gilead Sciences under the tradenames Emtriva(R) and Viread(R), respectively. ... Pay-Per-View - PR Newswire - HighBeam Research Gilead Sciences Announces Third Quarter 2007 Financial Results - Oct 18, 2007 Sales of Viread(R) (tenofovir disoproxil fumarate) were $149.1 million in the third quarter of 2007, a 13 percent decrease from $170.6 million in the third ... Genetic Engineering News - Genetic Engineering News (press release) Gilead Sciences Announces Third Quarter 2006 Financial Results. - Oct 18, 2006 Sales of Viread([R]) (tenofovir disoproxil fumarate) were $170.6 million in the third quarter of 2006, a 10 percent decrease from $189.4 million in the ... Free with registration - Business Wire - AccessMyLibrary.com Gilead Sciences, Inc. Companies ink licensing agreement for HIV … - Apr 20, 2005 ...rights for Truvada (emtricitabine and tenofovir disoproxil fumarate), Viread (tenofovir disoproxil fumarate), and Emtriva (emtricitabine) in Japan. ... Pay-Per-View - Biotech Week - Factiva, from Dow Jones Gilead Submits Marketing Applications in the United States and... - Oct 11, 2007 ..."The active ingredient in Viread -- tenofovir disoproxil fumarate -- is the most widely prescribed molecule for the treatment of HIV in the United States," ... Genetic Engineering News - Genetic Engineering News (press release) GILEAD SCIENCES REPORTS 2ND QTR REVENUES OF $1.28 BILLION … - Aug 1, 2008 Viread[R] (tenofovir disoproxil fumarate) sales were $150.7 million for the second quarter of 2008, a three percent decrease from $154.9 million in the ... Entrepreneur Netherlands Corporate News - Gilead Sciences maakt … - Apr 19, 2007 Viread Sales of Viread(R) (tenofovir disoproxil fumarate) were $160.7 million in the first quarter of 2007, a 16 percent decrease from $191.8 million in the ... Netherlands Corporate News - Netherlands Corporate News (persbericht) Netherlands Corporate News - Gilead Sciences meldt derde … - Oct 19, 2006 Viread Sales of Viread(R) (tenofovir disoproxil fumarate) were $170.6 million in the third quarter of 2006, a 10 percent decrease from $189.4 million in the ... Netherlands Corporate News - Netherlands Corporate News (persbericht) Landmark Five-Year Data on Gilead's Anti-HIV Drug Viread(R) Presented... - Sep 27, 2006 Viread is a component of two once-daily fixed-dose combination tablets, Truvada(R) (emtricitabine and tenofovir disoproxil fumarate), and ATRIPLA(TM) ... Genetic Engineering News - Genetic Engineering News (press release) 96-Week Data from Gilead's Study 934 Comparing Viread(R) and Emtriva … - Aug 14, 2006 Since ATRIPLA contains efavirenz, emtricitabine and tenofovir disoproxil fumarate, it should not be coadministered with Sustiva, Emtriva, Viread, ... Free with registration - Business Wire - AccessMyLibrary.com US FDA Grants Traditional Approval for Gilead's Once-Daily HIV … - Mar 8, 2006 Guidelines issued by the US Department of Health and Human Services (DHHS) list emtricitabine and tenofovir disoproxil fumarate as preferred agents for use ... RedOrbit Netherlands Corporate News - Amerikaanse FDA geeft toestemming aan … - Aug 3, 2006 Guidelines issued by the US Department of Health and Human Services (DHHS) list emtricitabine and tenofovir disoproxil fumarate as preferred agents for use ... Netherlands Corporate News - Netherlands Corporate News (persbericht) Netherlands Corporate News - Bristol-Myers Squibb en Gilead meldt … - Sep 1, 2006 Guidelines issued by the US Department of Health and Human Services (DHHS) list the combination of emtricitabine, tenofovir disoproxil fumarate and ... Netherlands Corporate News - Netherlands Corporate News (persbericht) Merger and Acquisition Scenario - Apr 7, 2007 Gilead?s products include Truvada (tenofovir disoproxil fumarate and emtricitabine) ... Viread (Tenofovir Disoproxil Fumarate); Hepsera (Adefovir Dipivoxil) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Aug 19, 2006 Gilead markets Viread (tenofovir disoproxil fumarate), Emtriva (emtricitabine) and Truvada (emtricitabine and tenofovir disoproxil fumarate) for the ... $250.00 - Revere Reports - Revere Press Release: Amylin Pharmaceuticals to Webcast Third Quarter... - Oct 12, 2007 ...in the United States and European Union for Viread(R) (Tenofovir Disoproxil Fumarate) for the Treatment of Chronic Hepatitis B. from M2 Presswire. Pay-Per-View - M2 Presswire - HighBeam Research Merger and Acquisition Scenario - Sep 2, 2006 Gilead markets Viread (tenofovir disoproxil fumarate), Emtriva (emtricitabine) and Truvada (emtricitabine and tenofovir disoproxil fumarate) for the ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jun 16, 2007 Hepsera (Adefovir Dipivoxil); Viread (Tenofovir Disoproxil Fumarate) ... Gilead?s products include Truvada (tenofovir disoproxil fumarate and emtricitabine) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - May 13, 2006 Gilead markets Viread (tenofovir disoproxil fumarate), Emtriva (emtricitabine) and Truvada (emtricitabine and tenofovir disoproxil fumarate) for the ... $250.00 - Revere Reports - Revere Press Release: Bristol-Myers Squibb And Gilead Sciences Announce … - Oct 17, 2007 This product combines Sustiva or efavirenz, manufactured by Bristol-Myers, and Truvada or emtricitabine/tenofovir disoproxil fumarate, manufactured by ... Pay-Per-View - M2 Presswire - HighBeam Research Press Release: European Commission Approves ATRIPLA(R) (efavirenz … - Dec 17, 2007 Emtricitabine and tenofovir disoproxil fumarate are commercialized by Gilead Sciences, Inc. under the tradenames Emtriva(R) and Viread(R), respectively, ... Pay-Per-View - PR Newswire - HighBeam Research HIV/AIDS Therapy; Data released from study comparing Viread and … - Mar 14, 2005 This study was designed to compare a regimen of Viread (tenofovir disoproxil fumarate), Emtriva (emtricitabine), and Bristol-Myers Squibb's Sustiva ... Pay-Per-View - Pain & Central Nervous System Week - Factiva, from Dow Jones Gilead's 1st-qtr sales reach $692.9M, up 61%.(sales and earnings of … - May 15, 2006 Gilead says that its success has been driven by sales of its HIV product franchise, which includes Truvada (emtricitabine and tenofovir disoproxil fumarate) ... $4.95 - Pharma Marketletter - ECNext Gilead reports $2B revenue in 2005, up 53%.(Gilead Sciences Inc.)(Brie... - Feb 6, 2006 ...million contribution from Truvada (emtricitabine and tenofovir disoproxil fumarate) and $182.4 million from Viread (tenofovir disoproxil fumarate); ... $4.95 - Pharma Marketletter - ECNext HIV patients and health activists at the rally. (AFP) - May 11, 2006 Public interest lawyers who have provided technical support to the networks have argued that tenofovir disoproxil fumarate is a salt created from an ... Calcutta Telegraph B-MS and Gilead enter deal for HAART tablet.(Antiretroviral Therapy... - May 8, 2006 Truvada itself is a fixed-dose product that contains two of Gilead's anti-HIV medications, Viread (tenofovir disoproxil fumarate) and Emtriva ... $4.95 - Pharma Marketletter - ECNext Strides Arcolab ties up with US Co for anti-HIV drugs - Aug 16, 2006 ...(emtricitabine and tenofovir disoproxil fumarate) and Viread (tenofovir disoproxil fumarate) in over 90 countries under the 'Gilead Access Program'. ... Free with registration - PTI - The Press Trust of India Ltd - AccessMyLibrary.com Gilead Announces Preliminary 48-Week Data From Study 934 Comparing … - Feb 3, 2005 Truvada combines 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate in one tablet, taken once a day in combination with other ... $4.95 - Business Wire - ECNext Gilead Expands Global Access Program for HIV Therapies to Include … - Mar 16, 2005 E[acute accent]Gilead also announced the recent establishment of a facility in The Bahamas to manufacture tenofovir disoproxil fumarate (tenofovir DF), ... $4.95 - Business Wire - ECNext Gilead Sciences Announces First Quarter 2006 Financial Results - Apr 18, 2006 ...including the continued robust performance of Truvada(R) (emtricitabine and tenofovir disoproxil fumarate) and Viread(R) (tenofovir disoproxil fumarate) ... Genetic Engineering News - Genetic Engineering News (press release) HIV/AIDS; Researchers' work from the United Kingdom and United States... - May 17, 2006 According to recent research published in the journal HIV Medicine, "Tenofovir disoproxil fumarate (Tenofovir DF, TDF), the first nucleotide reverse ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Gilead Sciences Announces Second Quarter 2006 Financial Results. - Jul 20, 2006 Sales of Viread(R) (tenofovir disoproxil fumarate) were $167.4 million in the second quarter of 2006, a 20 percent decrease from $209.1 million in the ... Free with registration - Business Wire - AccessMyLibrary.com European Commission Approves ATRIPLA(R), the First Once-Daily … - Dec 17, 2007 Emtricitabine and tenofovir disoproxil fumarate are commercialized by Gilead Sciences, Inc. (Nasdaq: GILD) under the tradenames Emtriva(R) and Viread(R), ... Lifescience-online HIV/AIDS Therapy; Data released from study comparing Viread and … - Mar 18, 2005 This study was designed to compare a regimen of Viread (tenofovir disoproxil fumarate), Emtriva (emtricitabine), and Bristol-Myers Squibb's Sustiva ... Pay-Per-View - Genomics & Genetics Weekly - Factiva, from Dow Jones Business Update; Global Access Program for HIV therapies to include … - Apr 11, 2005 The Gilead Access Program makes Gilead's Truvada (emtricitabine and tenofovir disoproxil fumarate) and Viread (tenofovir disoproxil fumarate) available to ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones INDIA'S MATRIX GETS USFDA NOD FOR HIV DRUG. - Dec 7, 2007 Matrixs Tenofovir Disoproxil Fumarate is the first and only generic tentative ... Tenofovir Disoproxil Fumarate will help to meet the need for high quality, ... $4.95 - AsiaPulse News - ECNext |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |